指南与共识胸部肿瘤

无驱动基因改变的IV期非小细胞肺癌治疗:ASCO活指南2022.3版

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.3.
指南 / 共识 · J Clin Oncol · 2023-02-21

ASCO活指南针对无驱动基因改变的IV期非小细胞肺癌治疗,由常设专家小组定期系统审查文献并更新推荐。本版本为2022.3版,活指南及更新不替代治疗提供者的独立专业判断,也不考虑患者个体差异。

要点

  • ASCO活指南由常设专家小组定期系统审查文献并更新推荐。
  • 活指南及更新不替代治疗提供者的独立专业判断。
  • 活指南及更新不考虑患者个体差异。

核心结论

  • ASCO活指南针对无驱动基因改变的IV期非小细胞肺癌治疗,由常设专家小组定期系统审查文献并更新推荐。
  • 活指南及更新不替代治疗提供者的独立专业判断,也不考虑患者个体差异。

研究设计与样本

  • ASCO活指南由常设专家小组按ASCO指南方法学手册定期系统审查文献并更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2). Updates are published regularly and can be found at https://ascopubs.org/nsclc-non-da-living-guideline.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jaiyesimi IA, Owen DH, Ismaila N, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.3. J Clin Oncol. 2023. PMID: 36809066. doi:10.1200/JCO.22.02783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。